HMP has drug discovery and development collaborations with AstraZeneca, Eli Lilly, and Nestlé Health Science.
These partnerships validate our business model and quality of its drug discovery and development. Our collaboration with large pharmaceutical companies represents a new model of innovative drug discovery & development partnerships for the Chinese pharmaceutical R&D industry. This kind of risk/reward and IP sharing model could quickly advance China’s new drug R&D capability to global level.
In addition, HMP has formed research and strategic collaborations with renowned universities and institutes worldwide. We will continue to investigate and discuss other potential alliances with appropriate organizations.
HMP is seeking opportunities to collaborate with leading universities, research institutes, and pharmaceutical and biotechnology companies in the following areas:
- Joint drug discovery research
- Mechanism of action studies
- Joint clinical development
- In- and out-licensing drug candidates at various stages